By Sam Bradley. Originally published in partnership with Glossy and Digiday.
Executive Overview
The architecture of everyday wellness is undergoing a radical transformation. For generations, consumer healthcare operated on a predictable, paternalistic axis: a patient experienced a symptom, consulted a licensed physician, received a handwritten or digital prescription, and dutifully visited a traditional pharmacy. Today, that linear journey has been thoroughly dismantled. Driven by sweeping regulatory shifts, an explosion in over-the-counter (OTC) accessibility, and a profound cultural shift toward personal bodily autonomy, modern consumers are bypassing the doctor’s office entirely for their everyday healthcare needs.
The numbers underlying this shift are staggering. In the United States alone, OTC sales surged to an unprecedented $58.2 billion, up sharply from $44.3 billion just the previous year. Simultaneously, the U.S. Food and Drug Administration (FDA) has signaled an increasingly progressive stance, clearing pathways for powerful drugs to transition from prescription-only status to accessible OTC retail shelves.
Faced with this massive behavioral pivot, pharmaceutical and consumer healthcare marketers are enacting a dramatic playbook overhaul. To capture market share in a landscape where everyday patients act increasingly as empowered retail shoppers, traditional healthcare giants are adopting the high-speed, digital-first strategies historically reserved for Consumer Packaged Goods (CPG) monoliths. Brands that once relied almost exclusively on 30-second television spots and traditional medical journal placements are now aggressively reallocating budgets toward retail media networks, creator-led social campaigns, programmatic search, and generative artificial intelligence.
Yet, this transition is far from a simple copy-and-paste operation. As healthcare companies embrace the "fast-moving consumer healthcare" (FMCH) model, they must walk a delicate tightrope: balancing the rigorous scientific credibility demanded of medical brands with the agile, hyper-measurable demands of modern digital commerce.
Detailed Chronology: The Evolution of Healthcare Marketing
To understand how the pharmaceutical sector arrived at its current digital inflection point, it is necessary to examine the rapid sequence of structural spin-outs, executive migrations, and strategic realignments that have defined the past several years.
The Post-Pandemic Retail Awakening (2020–2023)
The foundation for the current CPG-ification of healthcare was laid during the global pandemic, which fundamentally altered how consumers conceptualized wellness and disease management. With traditional healthcare systems strained and telehealth becoming normalized, consumers began taking an active hand in managing minor ailments, sleep issues, nutritional gaps, and pain management.
Recognizing this behavior, major healthcare conglomerates began planting the seeds for internal restructuring. In 2020, Albert Hernandez—a seasoned CPG veteran with a 17-year tenure at Nestlé—joined Sanofi’s consumer health division, bringing with him a mandate to modernize how everyday remedies were marketed to the public.
The Birth of Opella and Independence (2024–2025)
The defining structural milestone occurred when French pharmaceutical titan Sanofi spun out its consumer healthcare business, creating an independent entity known as Opella. This transaction instantly forged an €825 million ($927 million) standalone business overnight, though Sanofi retained a strategic 48% stake.
Operating outside the bureaucratic constraints of a traditional pharma parent company, Opella immediately set out to re-engineer its commercial engine. By the first half of 2026, the company’s structural agility began yielding clear results: net sales climbed 3.6%, propelled almost entirely by hyper-accelerated e-commerce growth.
To execute this vision, Opella systematically poached top-tier talent from traditional CPG powerhouses:
- March 2025: Gonzalo Balcazar, formerly of Reckitt, was brought on board as President of Europe and Latin America.
- July 2025: Victoria Tiffin transitioned from Procter & Gamble to assume the role of Chief Sales Officer.
- Ongoing Appointments: Murali Rao, with an extensive pedigree at Reckitt and dairy giant FrieslandCampina, was appointed Head of Brand and Innovation for Africa, the Middle East, and Turkey (AMET).
The Digital Acceleration and In-Housing Era (2025–2026)
With its leadership team firmly entrenched in CPG methodologies, Opella restructured its media investments. The company shifted a remarkable 60% of its total media budget into digital channels—leaving just 40% for legacy pharma mainstays like television and out-of-home advertising.
To manage the velocity required for this digital shift, Opella built an 85-person in-house creative and technical team. Following the operational footprints left by CPG pioneers like Unilever, this internal unit deployed generative AI tools to rapidly produce and version digital creative assets across multiple markets. Simultaneously, the company brought its search and programmatic media buying operations in-house, drastically cutting down time-to-market and lifting return on investment (ROI).
Supporting Context & Metrics
The transformation experienced by Opella is indicative of a broader, sector-wide migration. Competitors such as Kenvue (another high-profile pharma spin-out) are aggressively contesting the same retail and digital spaces. Direct-to-consumer healthcare brands are making massive cultural bets, such as Hims & Hers securing high-visibility real estate with a Super Bowl commercial.
Industry-wide forecasts underscore this aggressive pivot. Total digital ad spend within the pharmaceutical and healthcare sector is projected to hit a landmark $26.3 billion this year.
The Shift in Consumer Trust and Behavior
According to Hyun Lee-Miller, Chief Media Officer at agency Good Apple, this massive reallocation of capital toward social platforms and creator marketing is rooted in fundamental shifts in human psychology.
"When people make personal health decisions, they trust peer-to-peer lived experiences more than traditional ads," explains Lee-Miller. "Patients increasingly expect the same kind of access, choice, and convenience they have in other parts of their lives, and go-to-market strategies are adapting to that."
Lee-Miller notes that as traditional physician access shrinks due to overburdened healthcare systems, digital tools have given everyday people unprecedented autonomy. Consequently, brands are forced to invest heavily in multi-channel patient campaigns designed to educate, reassure, and guide consumers through a complex, self-directed decision-making journey.
The CMI Media Group Perspective
Sandy Weag, Client President at CMI Media Group, echoes this assessment, emphasizing that the modern healthcare consumer behaves identically to a retail shopper evaluating household goods or cosmetics.
"Historically, people relied more on their physicians," Weag notes. "[Now] people are taking a much more proactive approach to their health, and are making product decisions as a shopper, similar as they would any other consumer product."
Furthermore, Weag points out that healthcare clients are increasingly demanding the same level of accountability and performance-oriented attribution that traditional CPG brands enjoy. The days of accepting vague brand awareness metrics are fading; brands now expect immediate, trackable sales links from their media investments.
Official Statements and Industry Insights
The tension between traditional pharmaceutical conservatism and agile CPG disruption forms the core narrative of modern healthcare marketing.
Albert Hernandez, Chief Growth Officer at Opella, has been vocal about the death of legacy healthcare advertising models. In interviews detailing the company’s strategic evolution, Hernandez has coined the term "Fast-Moving Consumer Healthcare" (FMCH) to describe the intersection of rigorous scientific compliance and high-velocity retail marketing.
"We have to embrace a new way of operating," Hernandez stated. "If I believe I’m going to do that using the traditional pharma model of 30-second TV ads, that’s not going to work."
Hernandez points to the dramatic scaling of the company’s e-commerce footprint as proof of the model’s efficacy. Over a three-year period, Opella’s direct digital sales grew from a modest 4% of total revenue to an impactful 12%.
However, Hernandez is also quick to acknowledge that entering the CPG arena introduces novel, complex operational friction points. For instance, as Opella leans deeper into retail media networks (RMNs), internal and agency stakeholders must constantly debate and negotiate corporate turf wars over who ultimately controls retail media spend—the brand marketing teams, the e-commerce divisions, or traditional sales units.
Moreover, Hernandez highlights the looming challenge of artificial intelligence search engines. As large language models (LLMs) increasingly become the primary gateway through which consumers seek medical advice, healthcare marketers are forced to invest heavily in LLM citation tracking and visibility monitoring to ensure their products are recommended accurately by AI agents.
Future Outlook: Navigating the Traps of the CPG Playbook
While the adoption of the CPG playbook has unlocked unprecedented growth, agility, and measurable ROI for healthcare spin-outs, industry analysts are beginning to sound notes of caution. Blindly importing CPG strategies into the healthcare sector exposes brands to unique systemic vulnerabilities.
The S&P 500 Reality Check
Mass-market CPG companies are currently facing an existential reckoning. Historically dominant consumer goods giants are underperforming relative to the broader S&P 500. Recent data from NielsenIQ revealed that American grocery and supermarket sales of traditional food and CPG products plummeted by a staggering 9.3 billion units over a five-year period. This points to a fatigued consumer base reacting against aggressive pricing strategies, brand saturation, and a loss of authentic brand affinity.
If healthcare marketers lean too heavily into short-term, performance-obsessed CPG tactics—such as relentless promotional discounting and hyper-frequent algorithmic pivoting—they risk eroding the foundational trust that medical-adjacent brands require. Scientific rigor cannot be entirely subordinated to click-through rates.
The Balance of Long-Term Brand Building and Short-Term Attribution
The central challenge for healthcare CMOs moving forward will be mastering a delicate balancing act. On one hand, they must satisfy CFOs and skeptical C-suites demanding immediate, measurable sales attribution through digital and performance channels. On the other hand, they must invest deeply in long-term brand equity, medical credibility, and safety compliance.
As the lines between pharmacy aisles, e-commerce checkouts, and algorithmic health advice continue to blur, marketers like Hernandez, Lee-Miller, and Weag will serve as the architects of a new commercial reality. The ultimate winners of the great healthcare pivot will not be those who blindly copy the CPG playbook, but those astute enough to discern which modern retail strategies accelerate human wellness—and which traditional pharmaceutical safeguards are simply too valuable to leave behind.
